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Truncation of the envelope cytoplasmic tail has enabled FIV, SIV, and some laboratory HIV-1 strains to acquire broader cellular tropism
and enhanced fusogenicity. Here we have characterized a primary CD4-independent HIV-1 isolate (92UG046-T8) with a truncated
cytoplasmic tail that was able to infect and induce syncytia in primary lymphocytes from human, chimpanzee, and monkey, as well as CD4-
negative cell lines from human and monkey. Increased syncytia were also noticeable with 293 cells expressing the cloned envelope from the
92UG046-T8 isolate suggesting envelope-mediated cellular fusion. Except pooled serum from HIV-1-infected individuals, monoclonal anti-
envelope antibodies or antibodies/antagonists against CD4, CXCR4, and CCR5 were not able to prevent infection by the 92UG046-T8
isolate. This is the first report showing a primary HIV-1 variant with truncated cytoplasmic tail which is highly fusogenic and can infect a
broad range of cells from human and non-human origins. In vivo evolution of similar HIV-1 mutants may have important implications in
AIDS pathogenesis.
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The envelope glycoprotein of the human immunodefi-
ciency virus (HIV) plays a pivotal role for infection and
target cell selection. HIV envelope is synthesized as a
precursor protein (gp160), which is processed into surface
gp120 (SU) and transmembrane gp41 (TM) subunits by
cellular protease. Although the SU domain contains the
primary receptor/co-receptor binding regions, the TM
protein of the viral envelope also plays an important role
in the eventual virus-cell fusion and determination of the
target cells (Freed, 2001; Willey et al., 1988; Yang and
Compans, 1996). It has been previously shown that changes0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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cally alter virus infectivity, fusogenicity as well as cytopa-
thicity of primate lentiviruses (Bergeron et al., 1992; Chen,
1994; Dubay et al., 1992a; Freed and Myers, 1992; Freed et
al., 1990, 1992; Helseth et al., 1990; Owens et al., 1994).
One unusual feature of most lentiviruses is the long
cytoplasmic tail of the TM protein. While most retroviruses
have a cytoplasmic domain that is generally less than 35 aa
long, the cytoplasmic tail of the SIV and HIV isolates are
usually composed of over 150 amino acids (Earl et al.,
1991; Kowalski et al., 1987). The specific purpose of a long
cytoplasmic tail for these viruses remains unclear. A
premature stop codon in the envelope TM protein of several
SIV (Chakrabarti et al., 1987; Hirsch et al., 1987) and HIV-2
isolates (Hahn et al., 1987; Zagury et al., 1988) has resulted
in mutants with short cytoplasmic tail. The SIV mutants
with truncated cytoplasmic tail exhibited enhanced fuso-005) 30 – 44
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cells, including cells of human origin, compared to the wild-
type viruses (Chakrabarti et al., 1989; Hirsch et al., 1989;
Johnston et al., 1993; Kodama et al., 1989; Ritter et al.,
1993; Spies and Compans, 1994; Zingler and Littman,
1993). Truncation of the envelope cytoplasmic tail of the
human T cell leukemia virus type 1 (HTLV-1) has also
enabled fusion with otherwise resistant cell lines from other
species suggesting a link between short tail and widening of
the target cell types (Kim et al., 2003). Feline immunode-
ficiency virus (FIV) (Lerner and Elder, 2000), equine
anemia virus (EAV) (Rice et al., 1990), and maedi-visna
virus (MVV) (Zeilfelder and Bosch, 2001) mutants have
also shown enhanced fusogenicity and infectivity after
deletion of their envelope cytoplasmic tails. In fact, the
enhanced viral fusogenicity and/or infectivity associated
with the truncation of the cytoplasmic tail are not limited to
the lentivirus family alone. The removal of the C-terminal
16 amino acids from the cytoplasmic tail, the R peptide,
resulted in a more fusogenic murine leukemia virus (MuLV)
(Aguilar et al., 2003; Green et al., 1981) and similar changes
in the TM domain have been associated with increased
fusion with the Mason–Pfizer monkey virus (M-PMV)
(Brody et al., 1992) and the gibbon ape leukemia virus
(GaLV) (Christodoulopoulos and Cannon, 2001).
The biological effects of truncation of the envelope
cytoplasmic tail of HIV-1 have been studied with some
laboratory mutants (Edwards et al., 2001; Gabuzda et al.,
1992; Hoffman et al., 1999; LaBranche et al., 1999;
Mulligan et al., 1992; Murakami and Freed, 2000; Piller
et al., 2000; Wilk et al., 1992). Although most studies have
reported reduced infectivity of the HIV-1 variants with
truncated cytoplasmic tail, these mutants almost always
showed enhanced fusogenic capacity in spite of low viral
titers (Dubay et al., 1992b; Gabuzda et al., 1992; LaBranche
et al., 1999). KB-2 was the first reported HIV-1 strain with a
truncated cytoplasmic tail that originally came from a
Japanese patient who had AIDS. However, this mutant
was isolated from a chronically infected T cell line by serial
passage for extended period of time (Shimizu et al., 1990).
More recently, another HIV-1 mutant with a short TM
domain was isolated by long-term passage of an early HIV-1
reference strain (RF) in transformed H9 cells. Interestingly,
this short-tail HIV-1 mutant also exhibited extreme fuso-
genic properties in vitro (Jones et al., 2002). It was assumed
that these short-tail HIV-1 mutants might have emerged
under selection pressure during in vitro propagation of the
primary isolates on tumor cell lines. Thus, it remains unclear
whether cytoplasmic tail-deleted HIV-1 viruses may evolve
in vivo. The potential biological effects of the cytoplasmic
tail deleted HIV-1 strains also remains unknown at the
present time. In vivo evolution of an increasingly fusogenic
strain with a broad cellular tropism may have important
implications in HIV-1 disease pathogenesis. We have
recently reported isolation of CD4-independent HIV-1
variants from several patients. One of these isolates wasfound to have a truncated envelope cytoplasmic tail
(Zerhouni et al., 2004b). In this study, we have examined
the broad tropism of this unique CD4-independent HIV-1
isolate with a deleted TM domain and compared it with the
parental isolate that had a full-length envelope and that
generally maintained a normal CD4/X4-tropic phenotype.Results
HIV-1 isolate with a truncated envelope cytoplasmic tail
We have recently described the isolation of CD4-
independent HIV-1 variants from the bulk viral quasispecies
of a number of patients. One of these CD4-independent
isolates, 92UG046-T8, was found to have a sharply
truncated envelope cytoplasmic tail due to a premature
stop-codon in the TM domain (Zerhouni et al., 2004b). It
became clear from the very early stage of isolation of the
92UG046-T8 strain that this isolate was extremely fuso-
genic for both CD4+ and CD4-negative cells. In contrast,
the parental 92UG046 isolate was fusogenic only for CD4+
cells and PBL, but not for CD4-depleted PBL (data not
shown). It was unlikely that the CD4-independent and
fusogenic 92UG046-T8 isolate emerged in vitro during the
isolation process for several reasons. First, the 92UG046-T8
strain was isolated from the parental 92UG046-infected
primary CD8+ lymphocytes in short-term (2–3 weeks) co-
cultures. Next, unlike the previously described HIV-1
mutants with truncated cytoplasmic tail that emerged from
transformed cell lines (Jones et al., 2002; Shimizu et al.,
1990), the 92UG046-T8 isolate was never cultivated with
any tumor cell lines that could produce a selective pressure
for mutation. To further affirm that the truncated envelope
sequence of the 92UG046-T8 isolate was indeed pre-
existing in the parental 92UG046 isolate, we designed a
novel heteroduplex tracking assay (HTA) to detect the stop
codon within the gp41 sequence of the 92UG046-T8 isolate.
Comparison of the original 92UG046 isolate and the env
clones derived from the CD4-independent 92UG046-T8 as
well as the dominant 92UG046 isolates by HTA showed
that the 92UG046-T8 sequence with the stop codon in the
envelope cytoplasmic tail was present in the parental
92UG046 isolate at approximately 10% of the RNA pool
suggesting that the 92UG046-T8 isolate with a truncated
envelope was present as a minority variant in the viral
quasispecies of this patient (Fig. 1).
Another striking feature that was noticeable early during
the isolation of the 92UG046-T8 strain from the infected
CD8+ cell co-cultures was the conspicuous absence of
significant level of viral p24 antigens in the culture
supernatants in spite of an abundance of prominent syncytia
in these co-cultures. The 92UG046-T8-infected culture
supernatants also showed little RT activity and contained
low levels of viral RNA although these cultures remained
consistently HIV positive by PCR (data not shown).
Fig. 1. Hetoroduplex tracking assay (HTA) of the gp41 cytoplasmic domain
showing the presence of 92UG046-T8 clone sequence as a minority variant
in the original bulk viral quasispecies (92UG046). HTA was performed
using RT-PCR product from the original 92UG046 isolate and PCR
products from the cloned envelopes from the dominant 92UG046 variant
and the 92UG046-T8 isolate. The filled circle indicates the position of the
truncated variant, the open circle indicates the position of the read-through
variant. The asterisk indicates the position of the probe homoduplex.
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92UG046-T8-infected culture supernatants showed the
presence of high levels of infectious viral particles (TCID50)
as measured by de novo infection and syncytium induction
in MT-2 cells (Table 1). We have previously shown that the
92UG046-T8, but not its parental 92UG046, isolate also
produced syncytia in CD8+ cells (Zerhouni et al., 2004b). In
contrast, the original 92UG046 isolate produced syncytiaTable 1
Infection of cells by the 92UG046, 92UG046-T8, and IIIB isolatesa
Cells 92UG046b
Primary CD4+ cells (human) + (p24,RT,SI,IU)
Primary CD8+ cells (human) 
Primary lymphocytes (monkey) 
Primary lymphocytes (chimpanzee) 
MT-2 (human) + (p24,RT,IU,SI)
CEM (human) + (p24,RT,IU,SI)
U87 (human) 
U87-CD4-CXCR4 (human) + (p24,RT,IU,SI)
HeLa (human) 
HeLa-T4 (human) + (p24,RT,IU,SI)
COS-7 (monkey) 
a Infection of different primary cells or cell lines were performed with cell-free vira
and methods.
b Infectivity of various cells were determined by p24 ELISA (p24) (positive limit
appropriate controls); IU, infectious unit (positive limit determined by increasin
detected by microscopic examination); and co-cultures (CoC) (positive limit deteand high levels of p24 antigens in CD4+ cells and PBLs but
not in purified CD8+ cells (Table 1). Together, these results
suggest that the 92UG046-T8 isolate with a short envelope
cytoplasmic tail that was present as a minority variant in the
quasispecies (92UG046) was highly fusogenic for both
CD4+ and CD8+ cells. Similar results have been reported
with other HIV-1 mutants with truncated envelope cyto-
plasmic tail that produced increased number of syncytia in
spite of reduced virus production (Gabuzda et al., 1992;
Piller et al., 2000).
Infection of CD4+ and CD8+ lymphocytes
We have previously shown that the 92UG046-T8 isolate
was able to induce syncytia in both CD4+ and CD8+ cells
(Zerhouni et al., 2004b). Although low levels of HIV-1
replication could be detected with primary CD8+ cell
population, such infections are believed to occur through
co-expression of CD4 molecules in a small percentage of the
CD8+ cells (Flamand et al., 1998; Kitchen et al., 2004). To
further analyze the infection and syncytium induction in
CD8+ lymphocytes by the 92UG046-T8 isolate, purified
CD8+ and CD4+ cells (or PBLs) from the same donor (a new
donor for each of four separate experiments in order to avoid
any donor-specific genetic bias) were infected simultane-
ously with the 92UG046-T8 or its parental 92UG046 isolate.
Infection of both CD4+ cells/PBLs and CD8+ cells by the
92UG046-T8 isolate resulted in rapid (1–2 days) induction
of syncytia (data not shown) and high levels of virus
production (Fig. 2A). Significant cytopathic effects were
also observed after infection of both PBLs and CD8+ cells
by the 92UG046-T8 isolate (Fig. 2B). Overall, there was no
measurable difference between the infections of CD4+ (or
PBLs) or CD8+ cells in the appearance or number of
syncytia, the level of infectious virus produced, or the
cytopathic effects with the 92UG046-T8 isolate. In contrast,
the parental 92UG046 isolate basically infected only the
PBLs (Fig. 1A) and CD4+ cells (data not shown). Infection92UG046-T8b IIIBb
+ (PCR,RT,IU,SI) + (p24,RT,SI,IU)
+ (PCR,RT,IU,SI) 
+ (PCR,RT,IU,SI) 
+ (PCR,RT,IU,SI) 
+ (PCR,RT,IU,SI) + (p24,RT,IU,SI)
 + (p24,RT,IU,SI)
+ (PCR,RT,IU,SI,CoC) 
+ (PCR,RT,IU,SI,CoC) + (p24,RT,IU,SI,CoC)
+ (PCR,RT,IU,SI,CoC) 
+ (PCR,RT,IU,SI,CoC) + (p24,RT,SI)
+ (PCR,RT,IU,SI,CoC) 
l supernatants using an MOI between 0.1 and 0.05 as described in Materials
above 200 pg/ml); RT assay (RT) (positive limit above 1000 cpm/ml with
g TCID50 titers in MT-2 cells); formation of syncytia (SI) (positive limit
cted by evidence of infection with other indicator cells).
Fig. 2. (A) Infection of PBLs and purified CD8+ cells from a healthy donor by the 92UG046-T8 isolate or its parental 92UG046 isolate. Equal number of cells
was infected with the two viruses at day 0 and culture supernatants were collected at regular intervals as indicated and assayed for the presence of infectious
viral particles (I.U.) on MT-2 cells. (B) Cytopathic effect in PBLs and CD8+ cells after infection with the 92UG046-T8 or parental 92UG046 isolate. Cells were
infected as described in panel A and cell death was monitored at regular intervals by trypan blue exclusion/PI staining. Control uninfected cells were also
cultured simultaneously for comparison of cytopathic effects (data not shown). (C) Analysis of CD4+ and CD8+ cells that are present in the PBLs after
infection with the 92UG046-T8 or its parental 92UG046 isolate. Equal number of PBL was infected either with the 92UG046-T8 isolate (middle column) or the
92UG046 isolate (right column) or left as uninfected control (left column) as in panel A and cells were stained with anti-CD4-Pcy5 or anti-CD8-PE antibodies
and analyzed by FACS at 1 day, 4 days, and 11 days after infection as indicated.
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CD4+ cell population; these syncytia were less abundant and
were produced at a slower rate (3–5 days) (data not shown).
Unlike the 92UG046-T8 isolate, infection of CD8+ cells by
the parental 92UG046 isolate led to little or no virusproduction (Fig. 2A) and little cytopathic effects (Fig. 2B).
Sharp increase in the production of infectious viral titers
(Fig. 2A) with concomitant killings of the infected cells (Fig.
2B) indicated efficient infection of both the CD4+ and CD8+
lymphocytes by the 92UG046-T8 isolate.
Fig. 2 (continued).
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molecules on PBLs (Fig. 2C) or CD8+ cells (data not
shown) after infection with the 92UG046-T8 or its parental
92UG046 isolate. As infection with the parental 92UG046
isolate progressed, the CD4+ cell population present in the
PBLs was selectively depleted and by 11 days post infection,
95% of the cells present in the PBL population were single
CD8+ indicating the true CD4-tropic nature of this isolate. In
marked contrast, no specific killings of the CD4+ cells were
observed after infection of the same PBL population by the
92UG046-T8 isolate even after 11 days when viral repli-
cation had already peaked. It was obvious that the marked
cytopathic effects that were seen in the 92UG046-T8-
infected PBL cultures caused a proportionate loss of both
the CD4+ and CD8+ cell types since even when most of the
cells present in the 92UG046-T8-infected PBL cultures were
dead by 11 days after infection (Fig. 2B), the phenotypes of
the remaining viable cells present in these cultures remained
almost identical to the uninfected control cells (Fig. 2C).
There was a relative increase in the CD8+ cells and
proportionate loss of CD4+ cells in the uninfected PBLcultures probably as a result of enhanced PHA stimulation of
the CD8+ cells. Nevertheless, loss of both the CD4+ and
CD8+ cells in the 92UG046-T8-infected PBL cultures
indicated a dual (CD4/CD8)-tropism for this isolate. Apart
from slight up-regulation in CD8 expression, there were no
other changes in the surface expression of the 92UG046-T8-
infected CD8+ lymphocytes (data not shown). Production of
increasing viral titers (Fig. 2A) and rapid induction of death
of the infected cells (Fig. 2B) established infection of the
CD8+ lymphocytes by the 92UG046-T8 isolate. Taken
together, these data demonstrate that unlike the parental
92UG046-T8 strain that primarily infected the CD4+ cells,
the 92UG046-T8 isolate was infectious and cytopathic for
both the CD4+ and CD8+ cells.
Antibody neutralization
CD4-independent HIV isolates are generally reported to
be more sensitive to antibody neutralization (Thomas et al.,
2003). The 92UG046-T8 isolate was tested for neutraliza-
tion by four different anti-envelope monoclonal antibodies
K. Saha et al. / Virology 337 (2005) 30–44 35that have exhibited potent anti-HIV activities in vitro as
described in the Materials and methods. The effects of
antibody neutralization were monitored in MT-2 cells after
infection with the 92UG046, 92UG046-T8, or IIIB isolate.
None of the four monoclonal anti-envelope antibodies had
any effects on infection or syncytium induction by the
92UG046-T8 isolate even though the parental 92UG046
isolate as well as the IIIB isolate were efficiently neutralized
by these anti-HIV antibodies. However, pooled plasma from
HIV-1-infected patients was able to neutralize the
92UG046-T8 isolate (Table 2). These data show that in
spite of being CD4-independent, the 92UG046-T8 isolate is
resistant to neutralization by different anti-envelope anti-
bodies. But the 92UG046-T8 isolate could be efficiently
neutralized by serum from HIV-infected individuals. Further
studies are necessary to know the exact reason for this
unusual resistance of the 92UG046-T8 isolate to mono-
clonal anti-envelope antibodies.
Sequence analysis and envelope fusion
Changes in the viral envelope are likely to be responsible
for the phenotypic differences and fusogenic potential
between the 92UG046-T8 and its parental 92UG046
isolates. We have previously reported the sequence of the
envelope of the 92UG046-T8 isolate that contained a
premature stop codon in the TM domain (Zerhouni et al.,
2004b). Others have also reported sequences from portions
of the env gene encoding the gp120 from the parental
92UG046 isolate (Cornelissen et al., 1996, 1997). To further
examine and compare the env genes from the 92UG046 and
92UG046-T8 isolates, we sequenced and cloned the
complete envelope of the 92UG046 isolate from infected
CD4+ cells (Fig. 3A). Between the env genes of the
93UG046-T8 and the 92UG046 isolates, only 4 aa differ-
ences (one each in V1/V2 and V5, and two in the TM
domain) were noticeable. The most remarkable of these
changes was a single point mutation (a G to A substitution)
in the 92UG046-T8 isolate that resulted in a premature stopTable 2
Neutralization of 92UG046, 92UG046-T8, and IIIB isolates by anti-HIV
antibodiesa
Viruses Antibodiesb
447-52D b12 268-D ID6 HIVIG
92UG046 NDc +d + + +
92UG046-T8     +
IIIB + + NDc + +
a Neutralization by antibody treatment was estimated by reduction in the
number of syncytia and viral titers as described in Materials and methods.
b As discussed in Materials and methods, four different monoclonal anti-
envelope antibodies or pooled plasma from HIV-1-infected patients
(HIVIG) were used to test neutralization.
c ND stands for ‘‘not done’’.
d Neutralization was considered positive when the average number of
syncytia per hpf were reduced by at least 50% and the viral titers were
reduced by >90%.codon (TGA) in the place of a tryptophan residue (TGG) in
the parental strain. This premature stop-codon in the
92UG046-T8 isolate caused a truncated cytoplasmic tail
that was 67 aa shorter in length when compared to its
parental strain (Fig. 3A).
To test whether the truncated envelope of the 92UG046-
T8 isolate was able to mediate the enhanced fusogenic
activity associated with this strain, the 293 cells were
transfected with a vector expressing the cloned 92UG046-
T8 env and tested for the env-mediated cell fusion.
Although absence of rev gene may affect expression of
HIV env (Jounai et al., 2003), the 293 cells transfected with
the 92UG046-T8 env gene expressed low but detectable
level of envelope (Fig. 3B). The presence of the 92UG046-
T8 env in the transfected 293 cells was also confirmed by
PCR and sequencing (data not shown). During culture of
the 92UG046-T8 env-expressing 293 cells alone, morpho-
logic changes indicative of cell fusion were noticeable in
293 cells expressing the 92UG046-T8 env, but not in 293
cells expressing either the 92UG046 or HXB2 env or 293
cells transfected with plasmids containing no envelope
(data not shown). Cellular fusion became more prominent
when the 92UG046-T8 env-expressing 293 cells were co-
cultured with uninfected CD4+ (MT-2), CD4-negative (B-
LCL) lymphoid cells (data not shown), or non-lymphoid
U87 cells (CD4-/CXCR4-/CCR5-), as large number of cells
sequestered forming huge multi-nucleated giant cells after
over-night co-cultures (Fig. 3C). Co-cultures of the unin-
fected U87 cells with the 293 cells that were either
transfected with the control plasmids lacking any envelope
(Fig. 3D) or 293 cells expressing control 92UG046 or
HXB2 env (data not shown) did not show any signs for
cellular fusion. Together, these results demonstrate that the
envelope of the 92UG046-T8 strain was able to mediate
the enhanced fusogenic phenotype associated with this
isolate.
Infection of human and non-human cells
Previous studies with different lentiviruses have sug-
gested that truncation of the transmembrane protein may
result in an expansion of the virus host cells range
(Johnston et al., 1993; Kodama et al., 1989; Lerner and
Elder, 2000; Spies and Compans, 1994). We examined the
infectivity of the 92UG04-T8 and its parental 92UG046
isolates on different CD4-positive and CD4-negative human
as well as non-human (monkey and chimpanzee) cells. As
summarized in Table 1, the 92UG046-T8, but not its
parental 92UG04 isolate or prototype X4-tropic IIIB isolate,
was able to infect a wide range of CD4+ as well as CD4-
negative cells from different origins. Distinctive syncytia
appeared within 2–6 days after infection of primary
lymphocytes from two monkeys and chimpanzees. Infec-
tion of the monkey/chimpanzee lymphocytes by the
92UG046-T8 isolate and not by its parental 92UG046
isolate was also evident by positive PCR and RT production
Fig. 3. (A) Comparison of the envelope sequences of the 92UG046-T8 and its parental 92UG046 isolates. The envelopes of the 92UG046-T8 and 92UG046
isolates were sequenced and aligned for comparison. The prototype envelope sequences of the HXB2 isolate is on the top for analysis. The identical amino
acids are marked by dashes and gaps are marked by dots. The five variable (V) loops and transmembrane region (gp41) have been highlighted. The four amino
acid differences between the 92UG046-T8 and 92UG046 isolates including the premature stop codon (marked with an asterisk) for the 92UG046-T8 isolate are
shown in bold and also underlined for identification. (B) Expression of the 92UG046-T8 envelope in 293 cells. The 293 cells were transfected with the cloned
envelope from the 92UG046-T8 isolate (92UG046env) or with a plasmid lacking an envelope (no envelope) as indicated and stained with human anti-HIV
antibodies followed by FITC-labeled anti-human antibody and analyzed by FACS. (C–D) Fusion of U87 cells with 293 cells expressing 92UG046-T8
envelope. 293 cells expressing the 92UG046-T8 envelope (C) or transfected with a plasmid lacking an envelope (D) were co-cultured with uninfected U87 cells
as described in Materials and methods. Development of cell fusion was monitored microscopically. Arrows point to the fused cells that were recorded 24 h afte
the cells were mixed.
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Fig. 3 (continued).
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p24 antigen could be detected in the infected culture
supernatants.
The 92UG046-T8 isolate was also able to infect CD4-
negative transformed cell lines of human (U87 and HeLa)
and monkey (COS-7) origins that are generally resistant to
HIV-1 infection. Low levels of RT activity were detected
after infection of these non-lymphoid cells with the
92UG046-T8 isolate, likely because of reduced virus
production (Table 1). Prominent syncytia were noticeable
in U87 (Fig. 4A), HeLa and COS-7 (data not shown) cells
after infection with the 92UG046-T8 isolate, but not with
the parental 92UG046 (data not shown) or IIIB isolate (Fig.
4B). U87 cells are negative for expression of CD4 as well
as commonly used HIV-1 co-receptors including CXCR4
and CCR5. We have previously shown that infection by the
92UG046-T8 isolate is independent of CD4 (Zerhouni et
al., 2004b). Our results in this study indicate that infection
by the 92UG046-T8 isolate is also likely to be independentof the common HIV co-receptors. Induction of syncytia by
the 92UG046-T8 isolate in non-lymphoid human and
monkey cell lines generally took longer (9–20 days)
compared to the CD4+ T cell lines like the MT-2 cells or
primary lymphocytes (1–4 days). However, it was evident
that the non-lymphoid cell lines like the COS-7 cells
became productively infected with the 92UG046-T8 isolate
(Fig. 4D), but not the parental 92UG046 (Fig. 4C) or IIIB
isolate (data not shown), as these cells produced remarkable
syncytia when co-cultured with uninfected MT-2 cells even
after two (or more) passages of the infected COS-7 cells.
Such results are only possible with productive infection of
the COS-7 cells. Interestingly, not all human cell types were
susceptible to infection with the 92UG046-T8 isolate. For
example, CEM, a commonly used human CD4+ T cell line,
was found resistant to infection or syncytium induction
with the 92UG046-T8 isolate even though the parental
92UG046 isolate was able to infect and form syncytia with
these cells (Table 1). The reason for the apparent resistance
Fig. 4. (A–B) Induction of syncytia in U87 cells after infection with the
92UG046-T8 isolate. U87 cells were infected either with 92UG046-T8 (A)
or IIIB (B) isolates, passed at regular intervals, and monitored for induction
of syncytia for up to 8 weeks. Both pictures of syncytia shown here in the
92UG046-T8-infected cells (A) were taken after 3 passages (18 days after
infection). Simultaneous infections of the U87-CD4-CXCR4 cells were also
followed that produced similar syncytia by both the 92UG046-T8 and IIIB
isolates (data not shown). (C–D) Induction of syncytia by 92UG046-T8-
infected COS-7 cells. COS-7 cells were infected either with the parental
92UG046 (C) or the 92UG046-T8 (D) isolate and passaged twice. After the
second passage, the infected COS-7 cells were plated overnight and then
overlaid with equal number of uninfected MT-2 cells. Syncytium formation
was monitored daily. The syncytia (marked by arrows) with the 92UG046-
T8-infected co-cultures were observed 48 h after the addition of the MT-2
cells.
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unclear. However, cell-specific resistance against HIV
(Gabuzda et al., 1992; Iwatani et al., 2001; Murakami
and Freed, 2000; Reed et al., 2002) and SIV (Johnston et
al., 1993; Mulligan et al., 1992) mutants has been reported
in the past. Taken together, these results establish that the
92UG046-T8 isolate can infect a wide range of human and
non-human cells of both CD4-positive and CD4-negative
phenotypes.Discussion
In this study, we have characterized the broad cellular
tropism and high fusogenicity for both CD4-positive and
CD4-negative cells by a primary HIV-1 isolate, 92UG046-
T8 that has a sharply truncated envelope cytoplasmic tail.
Apart from infection of CD4-positive and CD4-negative
cells from humans, the 92UG046-T8 isolate was also
infectious and fusogenic for primary lymphocytes from
monkey and chimpanzee as well as transformed CD4-
negative cells (COS) of monkey origin indicating a broad
tropism for this isolate. An env clone derived from the
92UG046-T8 isolate was able to mediate syncytium
formation after transfection into CD4-negative 293 cells
suggesting that the truncated envelope of this isolate waslikely responsible for the enhanced fusogenic phenotype of
this strain. Our data also show that the 92UG046-T8 strain
is highly infectious and fusogenic even though it produces
little viral antigens (p24 and RT), making this isolate
difficult to detect by the commonly used assays for HIV
detection.
Retroviruses of different origins including HIV have
shown enhanced fusogenic activities, often in spite of
reduced virus production, when their envelope cytoplasmic
tails were truncated (Brody et al., 1992; Dubay et al., 1992a,
1992b; Earl et al., 1991; Gabuzda et al., 1992; Johnston et
al., 1993; Jones et al., 2002; Kowalski et al., 1987;
LaBranche et al., 1999; Lerner and Elder, 2000; Mulligan
et al., 1992; Ritter et al., 1993; Spies and Compans, 1994;
Zingler and Littman, 1993). An increase in the membrane
fusion activity may be a mechanism that enhances entry of
viruses into the target cells. Deletion of the cytoplasmic
domain of the Mason–Pfizer monkey virus has made the
mutant more fusogenic in spite of inefficient glycoprotein
incorporation (Brody et al., 1992; Dubay et al., 1992b). A
marked increase in cell fusion was also associated with FIV
(Lerner and Elder, 2000) and SIV (Johnston et al., 1993;
Zingler and Littman, 1993) mutants with truncated enve-
lope. A number of these short-tail lentiviruses emerged
spontaneously during propagation of the wild-type isolates
in unnatural host cells suggesting that selective pressure
may play a role in the emergence of these novel variants
(Hirsch et al., 1989; Kodama et al., 1989; Ritter et al.,
1993). There is precedent that HIV may also shed its long
cytoplasmic tail and infect a broad range of unusual cell
types. 8x, a IIIB mutant with a truncated envelope
cytoplasmic tail (8x) that emerged spontaneously during
the passage of the wild-type isolate on a CD4-negative T
cell line, became CD4-independent and showed enhanced
fusogenicity (LaBranche et al., 1999). The truncated
cytoplasmic tail of the 8x mutant was solely responsible
for the enhanced fusogenic activity and it played an
essential role for infection of the CD4-negative cells
(Edwards et al., 2002; LaBranche et al., 1999). Similarly,
the truncated cytoplasmic domain of an FIV mutant was
found to be exclusively responsible for its enhanced
fusogenic nature (Lerner and Elder, 2000). The truncated
envelope of the 92UG046-T8 isolate studied here was able
to induce fusion with cells that are generally resistant to
HIV entry including U87 cells that are negative for CD4,
CCR5, or CXCR4 (Fig. 3C). The enhanced fusogenic
ability of the 92UG046-T8 isolate was likely related to its
novel envelope structure. There were only 4 aa differences
in the envelope of the 92UG046-T8 isolate compared to its
parental strain that did not show CD4-independence or
enhanced fusogenicity. The most remarkable of these
sequence changes was the premature stop codon in the
TM region of the 92UG046-T8 isolate that led to a sharply
truncated cytoplasmic tail (Fig. 3A). Although future
mutagenesis and recombination studies would be necessary
to identify the precise roles played by the aa changes in the
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FIV, SIV, and HIV viruses (Chakrabarti et al., 1989;
Edwards et al., 2002; Hirsch et al., 1989; Kodama et al.,
1989; LaBranche et al., 1999; Lerner and Elder, 2000), the
truncated tail of the 92UG046-T8 isolate is likely respon-
sible for the highly fusogenic phenotype of this variant.
Cytoplasmic tail-deleted animal immunodeficiency viruses
found in vivo exhibited a broader cellular tropism suggest-
ing a possible evolutionary role for these mutants (Chakra-
barti et al., 1989; Hirsch et al., 1989; Kodama et al., 1989;
Lerner and Elder, 2000). The 92UG046-T8 isolate described
here was present as a minority variant in the original viral
quasispecies (Fig. 1), which strongly suggests that the
92UG046-T8 mutant emerged in vivo, possibly indicating a
niche in some patients for variants that can infect other cell
types.
Supernatants from cells infected with the 92UG046-T8
isolate contained little viral RNA, a low level of RT activity,
and almost undetectable viral p24 antigen, while the levels
of infectious viral particles (I.U.) in these supernatants
remained extremely high indicating highly infectious nature
of this isolate (Table 1, Fig. 2A). It seems that the
92UG046-T8 isolate may be efficient in spreading infection
by cell–cell viral transmission. Several studies have
suggested that truncation of the viral envelope may severely
affect infectivity because of defects in glycoprotein incor-
poration and/or essential Gag/Env interactions (Dubay et
al., 1992b; Freed and Martin, 1996; Murakami and Freed,
2000; Piller et al., 2000). Dubay et al. found that any
truncation from the cytoplasmic tail of more than 19 amino
acids almost completely abrogates infectivity of HIV-1
isolates (Dubay et al., 1992b). Similarly, Gabuzda et al.
have reported that RT activity in supernatants from cells
infected with HIV-1 mutants with truncated cytoplasmic tail
was reduced by more than 90% compared to the viruses
with full-length cytoplasmic tails (Gabuzda et al., 1992).
Interestingly, the tail-deleted mutants in these studies also
exhibited enhanced syncytium-inducing capacity in spite of
little virus production. Another study has indicated that the
increased formation of syncytia by a cytoplasmic tail-
deleted SIV mutant could be related to an over-expression
of the envelope protein on the cell surface even in the
absence of active virus replication (Johnston et al., 1993).
We did not observe any appreciable changes in the level of
92UG046-T8 envelope expression either on the infected
cells or cells transfected with the viral envelope. Truncation
of the TM domain of HIV-1, HIV-2, and SIV mutants have
been shown to influence fusion and infection activities by
altering the conformation of the external domain (SU) of the
viral envelope (Edwards et al., 2002; Hoffman et al., 1999;
Mulligan et al., 1992; Spies et al., 1994). The cytoplasmic
tail of the Moloney murine leukemia virus (MoMuLV)
envelope protein has also been shown to influence the
conformation of the extracellular domain (Aguilar et al.,
2003). We postulate that a significant reduction in the
length of the cytoplasmic tail of the 92UG046-T8 isolateprobably induced a conformational change in the receptor-
binding SU domain making this isolate inherently more
infectious and fusogenic in spite of reduced level of virus
production.
Our previous study has identified two different CD4-
independent isolates, 92UG046-T8 and 93US143-T8, that
were able to induce syncytia in CD8+/CD4 lympho-
cytes (Zerhouni et al., 2004b). Unlike the 92UG046-T8
isolate, the 93US143-T8 isolate was not able to infect or
induce syncytia in U87 cells (Zerhouni et al., 2004b). We
have recently shown that infection of CD8+/CD4 T
cells by the 93US143-T8 isolate is dependent on CXCR4
(Zerhouni et al., 2004a). Entry of the 92UG046-T8 isolate
into CD4-negative cells does not appear to be dependent
on CXCR4 as it can readily infect U87 cells that do not
express CXCR4 (Fig. 3C and data not shown). The exact
mode for viral entry into different cell types by the
92UG046-T8 isolate remains unknown at present. Inhib-
itors against known pathways for HIV-1 entry including
antibodies and/or antagonists against the CD4, CXCR4,
and CCR5 were also not able to block infection by the
92UG046-T8 isolate (unpublished observation). Several
anti-envelope monoclonal antibodies including the highly
potent b12 antibody (directed against the CD4-binding
region) were also unable to neutralize the 92UG046-T8
isolate (Table 2). Together, these results suggest that the
92UG046-T8 isolate may use a novel pathway(s) for
infection of CD4-negative cells (unpublished observation).
Studies are in progress to identify the exact mode of
entry for the 92UG046-T8 isolate into the CD4-negative
cells.
The prevalence of viruses with truncated cytoplasmic tail
like the 92UG046-T8 isolate in HIV-1-infected patients at
large remains unclear at the present time, as does the
clinical significance of this highly unusual HIV-1 variant
with broad tropism and enhanced fusogenicity. It is well
recognized that selection forces may greatly affect the
evolution of retroviruses (Overbaugh and Bangham, 2001).
A wide range of CD4-negative cells in vivo become
susceptible to HIV-1 infection with the advancement of
the disease indicating possible evolution of more robust
HIV-1 mutants (Bhattacharya et al., 2003; Doms, 2001;
Fauci, 1996). The emergence of HIV mutants with
truncated cytoplasmic tails and enhanced fusogenic poten-
tial in vivo would likely enhance infection of a wider
variety of different cell types. Although HIV strains that can
infect CD4-negative cells have been reported, these viruses
are usually found to be more sensitive to antibody
neutralization in vitro (Thomas et al., 2003), which may
not necessarily be relevant in vivo. Although the 92UG046-
T8 isolate could be neutralized in vitro by pooled sera from
asymptomatic HIV-infected individuals, the virus remained
resistant to several monoclonal anti-envelope antibodies
suggesting a more resistant nature for this isolate (Table 2).
But in spite of the robust nature of the 92UG046-T8 isolate,
it is not clear why this mutant existed only as a minority
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strain was isolated from a Ugandan patient with subtype D
infection, but apart from the AIDS status, very little
information is available about this patient (Cornelissen et
al., 1996, 1997). It is possible that the 92UG046-T8 isolate
emerged soon before the clinical sample was collected from
this patient. Nevertheless, there is little argument that the
emergence of HIV-1 mutants like the 92UG046-T8 isolate
in vivo would likely enhance infection of a wide range of
different cell types. In view of our findings in this study
coupled with the existing evidences from previous studies
with cytoplasmic tail-deleted HIV and SIV mutants (John-
ston et al., 1993; Jones et al., 2002; Kodama et al., 1989;
Shimizu et al., 1990), it will be important to search the viral
quasispecies in other patients, especially in the later stages
of HIV-1 disease for the existence of similar atypical HIV-1
mutants with truncated cytoplasmic tail and expanded
cellular tropism.Materials and methods
Viruses
The parental virus (92UG046) from which the cytoplas-
mic tail-deleted HIV-1 strain was isolated came from the
viral quasispecies of a Ugandan AIDS patient that was
originally collected in 1992 as part of the WHO Global
Program on AIDS (obtained through the NIH AIDS
Research and Reference Reagent Program (ARRRP);
catalog no. 1773). The cytoplasmic tail-deleted 92UG046-
T8 strain was isolated from the bulk viral quasispecies in
short-term culture through a stringent selection method from
infected CD8+ T cells that has been described recently
(Zerhouni et al., 2004b). Briefly, highly purified CD8+
lymphocytes from a healthy donor were infected with the
bulk quasispecies (92UG046) and 3 days after infection, the
purified CD8+ cells were further sorted by FACS to obtain
highly purified CD8+ cell population that was free from
CD4 mRNA. The 92UG046-T8 isolate was grown by short-
term (2–3 weeks) co-cultures of the infected and sort-
purified CD8+ cells with CD4-depleted PBMC from healthy
donors. The parental 92UG046 isolate was simultaneously
grown in PHA-stimulated CD4+ cells from normal donors
by standard method and used as control. Laboratory X4-
tropic IIIB, R5-tropic JR-FL, and several other known X4-
or R5X4-tropic primary isolates (92UG001, CMU08,
93US151) were also used as additional controls in these
experiments (Zerhouni et al., 2004b).
Cells and Infections
For the infection studies, purified CD4+ (or PBMC) and
CD8+ cells from healthy individuals were used. In addition,
human CD4-positive (MT-2, CEM) and CD4-negative
(U87, HeLa, 293) as well as CD4-negative (COS-7) monkeycell lines were also used for infection studies. In some
experiments, primary lymph node cells from two healthy
macaques and chimpanzees were used to test infectivity of
different viral isolates. Unless specifically mentioned, all
infections were performed with various HIV-1 isolates using
a multiplicity of infection (M.O.I.) between 0.1 and 0.05.
The culture conditions for isolation and infection of primary
PBLs or purified CD4+ and CD8+ cells have been described
in the past (Saha et al., 2001; Zerhouni et al., 2004b). All
primary cells were stimulated by PHA activation (1 Ag/ml)
for 48 h prior to infection and then cultured in IL-2
containing RPMI 1640 medium (supplemented with 10%
FCS). Infection and replication of different viral isolates
were monitored by p24 ELISA as well as by reverse
transcriptase (RT) assays. In addition, viral replication and
the presence of biologically infectious viruses were also
followed by calculating the infectious viral particles (I.U.)
present in the culture supernatants at different time points by
determining the 50% tissue culture infectious dose (TCID50)
with MT-2 cells through an end-point dilution using the
Reed-Muench accumulative method (Zerhouni et al.,
2004b). In some experiments with the non-permissive
CD4-negative cell lines (e.g., U87, HeLa, COS-7), infec-
tions were monitored by PCR and by co-culture (at 1:1
ratio) of the infected cells with other indicator cell lines at
various times after infection as indicated. These co-culture
experiments were often carried out after several passages of
the infected cells to rule out the possibility of any residual
viruses that may be present in the culture supernatants
without productive infection.
Syncytium induction and cytopathicity
Since short-tail viruses are known to induce enhanced
fusion (Dubay et al., 1992b; LaBranche et al., 1999),
induction of syncytia and cytopathic effects on infection
were closely followed in these experiments. Cell fusion
induced by different viral isolates was monitored micro-
scopically by following the development of syncytia in the
infected cells. Infected adherent cell lines that were mostly
of CD4-negative phenotype (e.g., U87, 293, COS-7) were
passed regularly with trypsin/EDTA digestion and formation
of syncytia in these cells was followed for up to 8 weeks.
Viruses produced by the infected cells in the culture
supernatants were further characterized for syncytium-
inducing (SI) phenotype by their ability to form syncytia
with MT-2 cells. The cytopathicity of different isolates was
followed by close monitoring of the number of viable cells
by trypan blue as well as PI staining (Zerhouni et al.,
2004b).
Antibodies and neutralization
Several known anti-HIVantibodies were used to test their
effects on infection by the 92UG046-T8 isolate. The
monoclonal antibodies used were Mab 447-52D, which
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envelope (Nyambi et al., 1998); Mab b12, which is directed
against the CD4 binding region of the envelope (Burton et
al., 1991); Mab 268-D, which reacts with the V3 epitope
HIGPGR (Gorny et al., 1991); and Mab ID6, which is
directed against the first 204 aa of gp120 of a recombinant
LAV-1 isolate (Dickey et al., 2000). These anti-envelope
antibodies are known to efficiently neutralize different
laboratory as well as clinical HIV-1 isolates. In addition,
human immunodeficiency virus immune globulin (HIVIG),
pooled plasma of several asymptomatic HIV-1-positive
donors that has broad HIV neutralizing activity, was also
used to test neutralization. These antibodies were obtained
through the ARRRP. In view of the unique nature of the
92UG046-T8 isolate that produced striking syncytia but
little p24 antigen after infection, modified neutralization
assay was performed. Briefly, each viral isolate (92UG046-
T8, 92UG046, or IIIB) were mixed with limiting dilution of
different anti-HIV antibodies (highest concentration of 20–
40 Ag/ml). Control samples were treated with isotype
control antibody for each monoclonal antibody used. After
incubation for 1 h at 37 -C, MT-2 cells were infected with
the virus-antibody mixture in triplicates. The number of
syncytia per hpf was counted and supernatants were
collected for viral assay (TCID50) at regular intervals.
Neutralization was measured by comparing the number of
syncytia present and the level of viral titers. At least 50%
reduction in the total number of syncytia and >90%
reduction in the viral titers were considered positive for
neutralization by each antibody.
Heteroduplex tracking assay (HTA) and cloning
The relative abundance of the gp41 stop codon sequence
variant present in the parental 92UG046 viral quasispecies
was determined through a novel approach by using a
specific HTA that included the premature termination site of
the 92UG046-T8 isolate. Briefly, viral RNA was isolated
using a QIAamp Viral RNA kit (Qiagen) from 140 Al
supernatant of the original 92UG046 isolate or the pellet
from 10 ml supernatant of the 92UG046-T8 isolate. A 148-
bp region of gp41 was amplified from the RNA by RT-PCR
using primers 1773for (5V-TTCAGCTACCACCGCTTGA-
GAGAC-3V, HXB numbering 8519-8542) and 1773rev (5V-
GCAAGCTAACAGCACTATTCTTTAGTTCC-3V, HXB
numbering 8666-8638). For the original 92UG046 RNA,
reverse transcription (RT) reactions consisted of 5 Al of the
eluted viral RNA, 1 AMV RT buffer (Roche), 1 mM each
of dNTP (Clontech), 15 pmol 1773rev primer, 10 U Rnase
inhibitor (Fisher Scientific), and 12.5 U AMV RT (Roche)
in a total volume of 10 Al. The RT reaction mixture
remained basically the same for the 92UG046-T8 RNA
except that 1 Expand High Fidelity buffer with MgCl2
was used and 0.67 mM each of dNTP and 20U Rnase
inhibitor were used for each reaction. Reactions were
incubated at 42 -C for 30 min and then at 95 -C for 5min to inactivate the AMV RT. All PCR reactions were
carried out as previously described (Zerhouni et al., 2004b).
The same region was amplified from two env clones derived
from 92UG046 and 92UG046-T8 RNA that did not and did
have the stop codon, respectively. A corresponding probe
was constructed by amplifying the same region from a YU-2
env subclone (Li et al., 1992) and ligating the product into
the pT7Blue-3 vector (Novagen). The downstream EcoRI
site was destroyed by Klenow fill-in. Mutagenesis was
performed using the Quick Change mutagenesis system
(Stratagene) to change the GGTGGGGAGT sequence to
GGTGGtGAGT, which placed a new mutation adjacent to
the site of the stop codon to form a cluster of mismatches in
the heteroduplex when the stop codon was present to change
the heteroduplex mobility. To label the probe on one strand
only, the probe sequence was cleaved on the upstream side
with EcoRI, end-labeled with 35S by Klenow fill-in, and
removed from the vector by digestion with HindIII. The
labeled probe and the products were mixed, heated at 95 -C
for 2 min, and allowed to cool at room temperature for 5
min before separation of the heteroduplexes on a 12% non-
denaturing polyacrylamide gel and the heteroduplexes
containing a labeled probe strand were visualized by
autoradiography and phosphorimaging. The relative abun-
dance of each band within a lane was determined using
Fragment Analysis software (Molecular Dynamics). The
RT-PCR product from the original 92UG046 isolate was
cloned into the pT7Blue-3 vector and clones were screened
by HTA. Clones of interest were sequenced to verify their
sequence against the 92UG046 env clone.
Viral envelope and fusion
The envelope of the 92UG046-T8 isolate was sequenced
and cloned previously (Zerhouni et al., 2004b). The whole
envelope of the parental 92UG046 isolate was also
sequenced and cloned for comparison following similar
procedures (Saha et al., 2001; Zerhouni et al., 2004b). The
fusogenic potential of the 92UG046-T8 env clone was
examined by a fusion assay (Dubay et al., 1992b). Briefly, a
low-copy-number plasmid expression vector, pWKS-BC,
was constructed in which the expression cassette containing
the CMV promotor and SV40 poly(A) was removed from
the pBK-CMV (Stratagene) with AflIII, the ends were
filled-in with Klenow and ligated into the PvuII-digested
low-copy-number plasmid pWKS30 (Wang and Kushner,
1991). The 92UG046-T8 env gene was cloned into the
EcoRI site in pWKS-BC to create pWBC-Env92UG046-T8.
The orientation of the envelope was affirmed by sequenc-
ing. Fresh 293 cells were seeded on a 60-mm tissue culture
dish to 60–70% confluence and co-transfected by a
modified calcium phosphate method (Jordan et al., 1996)
with 6 Ag of the pWBC-Env92UG046-T8 and 2 Ag of pBK-
CMV which carries a neor gene for G418 resistance. After
overnight incubation, the transfected cells were maintained
in selection medium.
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expression of the viral envelope through indirect FACS
analysis by staining first with pooled sera of asymptomatic
HIV-infected patients (obtained from the ARRRP; catalog
no. 3957) or normal human serum (as control), followed by
incubation with fluorescein isothiocyanate (FITC)-conju-
gated F(abV)2 goat anti-human IgG (Sigma) antibody. 293
cells transfected with the control plasmids but without any
envelope and 283 cells expressing the envelope of the
HXB2 isolate (obtained through the ARRRP) were used as
controls for these experiments. The envelope-expressing
293 cells were examined microscopically for any morpho-
logic changes for fusion. Envelope-mediated cell fusion was
further visualized by co-culture experiments. For this
purpose, a sub-confluent layer of the 293 cells expressing
the envelope of the 92UG046-T8 isolate (or control 293
cells) was cultured overnight and then overlaid with equal
number of uninfected cells. Cell fusion was examined
microscopically and also after staining with the May–
Grunwald/Giemsa stain (Dubay et al., 1992b).
Nucleotide accession numbers
The complete gp160 sequences of the 92UG046-T8 and
92UG046 isolates have been submitted to the GenBank
(accession numbers AY623599-AY623600).Acknowledgments
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